EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset

Philipp Klyscz iD, Klemens Ruprecht, Lina Carlotta Anderhalten, Tanja Schmitz-Hübsch iD, Jens Kuhle, Tatiana Usnich, Judith Bellmann-Strobl, Friedemann Paul, Patrick Schindler, Susanna Asseyer iD

European Journal of Neurology · 2025

DOI: 10.1111/ene.70375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Philipp Klyscz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité,…. Hauptthemen laut MEDLINE: Neurofilament Proteins, Multiple Sclerosis, Demyelinating Diseases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We compared the prognostic value of serum neurofilament light chain (sNFL) and glial fibrillary acidic protein (sGFAP) for clinical and radiologic disease activity among patients with clinically isolated syndrome or early multiple sclerosis (MS) with optic neuritis (pwON) and non‐optic neuritis (pwNON) as the first manifestation.

Methods

Patients within 7 months (pwON and pwNON) from disease onset and patients with MS with a disease duration longer than 12 months (pwMS) as controls were included. sNFL and sGFAP were analyzed at baseline and at follow‐ups using SIMOA technology. Linear mixed models and Cox regression analyses were applied.

Results

We included 165 samples of 86 patients (18 pwON, 46 pwNON, 21 pwMS). Median follow‐up time was 80 months. Mean sNFL z scores were higher in pwNON (1.06) than pwON (0.53) and pwMS (0.94). In pwNON, but not pwON, higher sNFL z scores were associated with an elevated risk for a subsequent attack (pwNON: HR 1.63 [95% CI 1.12 to 2.27], p = 0.005; pwON: HR 0.80 [95% CI 0.51–2.27], p = 0.318) and new MRI T2 lesions (pwNON: HR 1.66 [95% CI 1.31 to 2.11], p < 0.001; pwON: HR 1.16 [95% CI 0.82 to 1.63], p = 0.404). sGFAP z scores were associated with a lower risk of a subsequent attack in pwON (HR 0.34 [95% CI 0.12 to 0.98], p = 0.047). Conclusion sNFL but not sGFAP predicted future clinical and MRI disease activity only in pwNON, potentially suggesting that the prognostic value of sNFL may depend on the type of the first manifestation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsMultiple SclerosisDemyelinating DiseasesHumansFemaleMaleAdultOptic NeuritisMiddle AgedGlial Fibrillary Acidic ProteinDisease ProgressionPrognosisBiomarkersFollow-Up StudiesMagnetic Resonance Imaging

Stichwörter der Autor:innen

biomarkerglial fibrillary acidic proteinmultiple sclerosisneurofilamentoptic neuritis

Substanzen

Neurofilament Proteinsneurofilament protein LGlial Fibrillary Acidic ProteinBiomarkers

Autor:innen und Institutionen

  • Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Division of Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
  • Neuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Neurology, Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.

ORCID-Profile: Philipp Klyscz, Tanja Schmitz-Hübsch, Susanna Asseyer

Förderung

  • Novartis

Zitieren

APA

Klyscz, P., Ruprecht, K., Anderhalten, L. C., Schmitz-Hübsch, T., Kuhle, J., Usnich, T., Bellmann-Strobl, J., Paul, F., Schindler, P., & Asseyer, S. (2025). Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset. European Journal of Neurology. https://doi.org/10.1111/ene.70375

Vancouver

Klyscz P, Ruprecht K, Anderhalten LC, Schmitz-Hübsch T, Kuhle J, Usnich T, et al. Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset. European Journal of Neurology. 2025. doi:10.1111/ene.70375

BibTeX
@article{Klyscz2025,
  author = {Klyscz, Philipp and Ruprecht, Klemens and Anderhalten, Lina Carlotta and Schmitz-Hübsch, Tanja and Kuhle, Jens and Usnich, Tatiana and Bellmann-Strobl, Judith and Paul, Friedemann and Schindler, Patrick and Asseyer, Susanna},
  title = {Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70375}
}
Kostenlos starten →